Abstract: An automatic cleaning device, comprising: a moving platform configured to automatically move on an operation surface; a cleaning module which is provided on the moving platform and comprises a wet-type cleaning module configured to clean at least a part of the operation surface in a wet-type cleaning mode and a dry-type cleaning module configured to clean at least a part of the operation surface in a dry-type cleaning mode; and a floating lifting/lowering structure connected to the dry-type cleaning module and configured to enable the dry-type cleaning module to passively move up and down relative to the moving platform.

Abstract: An object of the present invention is to provide a stepped pin loading mechanism which can be used for loading stepped pins, comprising a vibrator bowl. A spirally rising discharge track is connected to an outer side of a hopper of the vibrator bowl, and a swivel plate is provided on the discharge track, and several receiving slots are provided on the swivel plate. The strip-shaped receiving slot consists of an inner segment and an outer segment, and the width of the outer segment is greater than that of the inner segment. A front baffle and a rear baffle, both of which are provided with a through opening, are provided on the discharge track, an arc-shaped side baffle, which is located between the front baffle and the rear baffle to form a semi-enclosed structure, is provided on an outer circumferential side of the swivel plate.

Abstract: An object of the present invention is to provide a stepped pin loading mechanism which can be used for loading stepped pins, comprising a vibrator bowl. A spirally rising discharge track is connected to an outer side of a hopper of the vibrator bowl, and a swivel plate is provided on the discharge track, and several receiving slots are provided on the swivel plate. The strip-shaped receiving slot consists of an inner segment and an outer segment, and the width of the outer segment is greater than that of the inner segment. A front baffle and a rear baffle, both of which are provided with a through opening, are provided on the discharge track, an arc-shaped side baffle, which is located between the front baffle and the rear baffle to form a semi-enclosed structure, is provided on an outer circumferential side of the swivel plate.

Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.

Abstract: An object of the present invention is to provide a thrust testing device for a linear actuator, which can test thrust more accurately and greatly reduce the working intensity of test operators.

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Abstract: An object of the present invention is to provide a thrust testing device for a linear actuator, which can test thrust more accurately and greatly reduce the working intensity of test operators.

Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.

Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.